OSM and breast carcinoma: While the predominant signaling pathway activated by the gp130 cytokines is the JAK-STAT signaling axis, OSM has been shown to suppress ER protein and mRNA expression in ER+ breast cancer cells through the MAPK-ERK pathway [55].